Literature DB >> 10965797

Nonoxidative protein glycation is implicated in familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation.

N Shibata1, R Nagai, S Miyata, T Jono, S Horiuchi, A Hirano, S Kato, S Sasaki, K Asayama, M Kobayashi.   

Abstract

To assess a role for oxidative stress in the pathogenesis of amyotrophic lateral sclerosis (ALS), we analyzed the immunohistochemical localization of 8-hydroxy2'-deoxyguanosine (OHdG) as a nucleic acid oxidation product, acrolein-protein adduct and 4-hydroxy-2-nonenal (HNE)-protein adduct as lipid peroxidation products, Nepsiloncarboxymethyl-lysine (CML) as a lipid peroxidation or protein glycoxidation product, pentosidine as a protein glycoxidation product, and imidazolone and pyrraline as nonoxidative protein glycation products in the spinal cord of three familial ALS patients with superoxide dismutase(SOD 1) A4V mutation, six sporadic ALS patients, and six age-matched control individuals. The spinal cord sections of the control cases did not show any distinct immunoreactivities for these examined products. In the familial ALS cases, intense immunoreactivities for pyrraline and CML were confined to the characteristic Lewy body-like hyaline inclusions, and imidazolone immunoreactivity was located in the cytoplasm of the residual motor neurons. No significant immunoreactivities for other examined products were detected in the familial ALS spinal cords. In the sporadic ALS cases, intense immunoreactivities for pentosidine, CML and HNE-protein adduct were seen in the cytoplasm of the degenerated motor neurons, and OHdG immunoreactivity was located in the cell nuclei of the residual neurons and glial cells. The present results indicate that oxidative reactions are involved in the disease processes of sporadic ALS, while there is no evidence for increased oxidative damage except for CML deposition in the familial ALS spinal cords. Furthermore, it is likely that the accumulation of pyrraline and imidazolone supports a nonoxidative mechanism in SOD1-related motor neuron degeneration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965797     DOI: 10.1007/s004019900173

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  13 in total

1.  S100B protein and 4-hydroxynonenal in the spinal cord of wobbler mice.

Authors:  Valentina Corvino; Rita Businaro; Maria Concetta Geloso; Paolo Bigini; Valentina Cavallo; Elena Pompili; Tiziana Mennini; Lorenzo Fumagalli; Fabrizio Michetti
Journal:  Neurochem Res       Date:  2003-02       Impact factor: 3.996

2.  ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis.

Authors:  Hirotaka Tanaka; Masamitsu Shimazawa; Masafumi Takata; Hideo Kaneko; Kazuhiro Tsuruma; Tsunehiko Ikeda; Hitoshi Warita; Masashi Aoki; Mitsunori Yamada; Hitoshi Takahashi; Isao Hozumi; Hiroshi Minatsu; Takashi Inuzuka; Hideaki Hara
Journal:  J Neurol       Date:  2013-02-23       Impact factor: 4.849

Review 3.  Antibody-based detection of advanced glycation end-products: promises vs. limitations.

Authors:  Ryoji Nagai; Jun-Ichi Shirakawa; Rei-Ichi Ohno; Kota Hatano; Hikari Sugawa; Shoutaro Arakawa; Kenta Ichimaru; Shoh Kinoshita; Noriyuki Sakata; Mime Nagai
Journal:  Glycoconj J       Date:  2016-07-15       Impact factor: 2.916

4.  Nitration and Glycation Turn Mature NGF into a Toxic Factor for Motor Neurons: A Role for p75NTR and RAGE Signaling in ALS.

Authors:  Mi Jin Kim; Marcelo R Vargas; Benjamin A Harlan; Kelby M Killoy; Lauren E Ball; Susana Comte-Walters; Monika Gooz; Yasuhiko Yamamoto; Joseph S Beckman; Luis Barbeito; Mariana Pehar
Journal:  Antioxid Redox Signal       Date:  2017-06-26       Impact factor: 8.401

Review 5.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Authors:  Emanuele D'Amico; Pam Factor-Litvak; Regina M Santella; Hiroshi Mitsumoto
Journal:  Free Radic Biol Med       Date:  2013-06-21       Impact factor: 7.376

6.  Anti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune encephalomyelitis mouse.

Authors:  G Leung; W Sun; L Zheng; S Brookes; M Tully; R Shi
Journal:  Neuroscience       Date:  2010-11-26       Impact factor: 3.590

Review 7.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

Review 8.  Neurodegenerative disorders and nanoformulated drug development.

Authors:  Ari Nowacek; Lisa M Kosloski; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

9.  Pentosidine accumulation in human oocytes and their correlation to age-related apoptosis.

Authors:  Miki Matsumine; Noriyuki Shibata; Ken Ishitani; Makio Kobayashi; Hiroaki Ohta
Journal:  Acta Histochem Cytochem       Date:  2008-08-28       Impact factor: 1.938

10.  Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis.

Authors:  Judyta K Juranek; Gurdip K Daffu; Joanna Wojtkiewicz; David Lacomis; Julia Kofler; Ann Marie Schmidt
Journal:  Front Cell Neurosci       Date:  2015-12-22       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.